Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
Karlijn de Joode(Erasmus MC Cancer Institute), C. R. van Rooijen, Frank J. Borm, Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Jessica S.W. Borgers(The Netherlands Cancer Institute), Yarne Klaver, Jan C. Drooger, Jan Willem B. de Groot(Isala), Pim Mutsaers(Erasmus MC Cancer Institute), F. Terhegggen(Zuyderland Medisch Centrum), Cordula Pitz, Brigitte C.M. Haberkorn(Maasstad Ziekenhuis), Hanneke W.M. van Laarhoven(Dutch Cancer Society), D.M. van Diepen, Mina Youssef(University at Buffalo, State University of New York), Marissa Cloos(Erasmus MC Cancer Institute), Cor H. van der Leest(Roche (Canada)), Nico G. J. van Diemen(Ziekenhuis Bernhoven), Luc J. A. Strobbe(Canisius-Wilhelmina Ziekenhuis), L.J.C. van Warmerdam, Laurens V. Beerepoot(Elisabeth-TweeSteden Ziekenhuis), Esther Oomen‐de Hoop(Erasmus MC Cancer Institute), Daphne W. Dumoulin(Erasmus MC), Otto Visser(Netherlands Comprehensive Cancer Organisation), Marije Slingerland(Leiden University Medical Center), Haiko J. Bloemendal(Meander Medisch Centrum), Veerle J. Nuij, Elisabeth G.E. de Vries(Karolinska University Hospital), Femke S. van der Meer, Hans M. Westgeest(Amphia Ziekenhuis), Erica J. Geraedts(Groene Hart Ziekenhuis), Geert A. Cirkel(St. Antonius Ziekenhuis), Eduard J. Libourel(Erasmus MC Cancer Institute), Raban Heller(Bundeswehrkrankenhaus), C.J. van Loenhout, Maureen J.B. Aarts(Maastricht University Medical Centre), Annemarie Becker‐Commissaris(Amsterdam University Medical Centers), M. Tiemessen(Erasmus MC), Jos A. Stigt, Franchette W.P.J. van den Berkmortel(Zuyderland Medisch Centrum), A.P. Hamberg(Erasmus MC), Jolien Tol(Jeroen Bosch Ziekenhuis), Ben E.E.M. van den Borne, Gerarda J.M. Herder, L. van Leeuwen(Mount Sinai Hospital), Lizza Hendriks(Maastricht University), J.W.G. van Putten, Susan C. van ‘t Westeinde
Cited by 78
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k